Biomphalaria glabrata amoebocytes: Effect of Schistosoma mansoni infection on in vitro phagocytosis

The rate of phagocytosis by amoebocytes obtained from hemolymph of the pulmonate Biomphalaria glabrata infected with the trematode Schistosoma mansoni for 24 hr and 2, 4, and 6 weeks has been determined using the monolayer assay system. Amoebocyte preparations from snails infected for 4 and 6 weeks showed a gradual decrease in the phagocytic rates compared to those from uninfected controls. Snails harboring the parasite for 4 and 6 weeks also showed a significant increase in the number of amoebocytes in the hemolymph. No significant changes were detected in the rate of phagocytosis or number of amoebocytes in snails infected for 2 weeks or less. Alterations in the morphology and behavior of amoebocytes from infected snails were also noted.     

Effect of bis(acetato)tetrakis(imidazole) copper(II) in delaying the onset and reducing the mortality rate of strychnine- and thiosemicarbazide—Induced convulsions

The anticonvulsant activity of bis(acetato)tetrakis(imidazole) copper(II), Cu(OAc)₂(Im)₄, was studied in normal mice using chemical convulsions induced by strychnine, thiosemicarbazide, picrotoxin, and pentelenetetrazol. Intraperitoneal administration of Cu(OAc) ₂(Im)₄, 50 mg/kg body mass, has delayed the onset of strychnine (3 mg/kg)-induced convulsion by 204% (p≤0.005) and thiosemicarbazide (20 mg/kg)-induced convulsant by 61% (p≤0.005). The changes in the onset of picrotoxin-(6 mg/kg) and pentelenetetrazol (50 mg/kg)-induced convulsions were not significant. The same dosage of the copper compound was effective in delaying the lethal time and reducing the mortality rate of treated animals. The anticonvulsant activity of Cu(OAc) ₂(Im)₄ complex against strychnine was not related to its constituents because the inorganic form of copper such as copper chloride, copper acetate, and the parent imidazole has no anticonvulsant activity. Other copper(II) complexes like copper(II)aspirinate and bis(acetato)bis(2-methyl imidazole) copper(II) were less effective.     

Transcriptomic Identification of ADH1B as a Novel Candidate Gene for Obesity and Insulin Resistance in Human Adipose Tissue in Mexican Americans from the Veterans Administration Genetic Epidemiology Study (VAGES)

Type 2 diabetes (T2D) is a complex metabolic disease that is more prevalent in ethnic groups such as Mexican Americans, and is strongly associated with the risk factors obesity and insulin resistance. The goal of this study was to perform whole genome gene expression profiling in adipose tissue to detect common patterns of gene regulation associated with obesity and insulin resistance. We used phenotypic and genotypic data from 308 Mexican American participants from the Veterans Administration Genetic Epidemiology Study (VAGES). Basal fasting RNA was extracted from adipose tissue biopsies from a subset of 75 unrelated individuals, and gene expression data generated on the Illumina BeadArray platform. The number of gene probes with significant expression above baseline was approximately 31,000. We performed multiple regression analysis of all probes with 15 metabolic traits. Adipose tissue had 3,012 genes significantly associated with the traits of interest (false discovery rate, FDR ≤ 0.05). The significance of gene expression changes was used to select 52 genes with significant (FDR ≤ 10^-4) gene expression changes across multiple traits. Gene sets/Pathways analysis identified one gene, alcohol dehydrogenase 1B (ADH1B) that was significantly enriched (P < 10^-60) as a prime candidate for involvement in multiple relevant metabolic pathways. Illumina BeadChip derived ADH1B expression data was consistent with quantitative real time PCR data. We observed significant inverse correlations with waist circumference (2.8 x 10^-9), BMI (5.4 x 10^-6), and fasting plasma insulin (P < 0.001). These findings are consistent with a central role for ADH1B in obesity and insulin resistance and provide evidence for a novel genetic regulatory mechanism for human metabolic diseases related to these traits.     

EFFECT OF SENSORY STIMULATION ON AMINO ACID INCORPORATION INTO BRAIN PROTEINS IN VIVO

Abstract— Stimulation (AES) of the brachial plexus of anaesthetised rats resulted in an increased incorporation of carbon from [U-¹⁴C]glucose into TCA-insoluble proteins in the contralateral cerebral hemisphere, as compared with the ipsi-lateral hemisphere. The greatest change was observed in the sensori-motor cortex grey matter.
Following intraventricular injections of [U-¹⁴C]glucose, the changes caused by brachial plexus stimulation were variable, depending on which hemisphere received the label. The injection itself severely inhibited the incorporation into protein. Neither the injection, nor stimulation affected the conversion of [U-¹⁴C]glucose into amino acids or its relative distribution between the two hemispheres.     

The Effects of Scorpion Venom Toxin on the Release of Amino Acid Neurotransmitters from Cerebral Cortex In Vivo and In Vitro

Tityustoxin, the active component of the venom of the Brazilian yellow scorpion Tityus serrulatus, caused specific release of the neurotransmitter amino acids glutamate, aspartate and GABA in vivo from the superfused sensori-motor cortex of conscious unanesthetised rats and in vitro from rat cortical synaptosomes. The effects on synaptosomes appear to be due to a depolarising action. Synaptosomal potassium levels were depleted by the toxin. The action was also blocked both in vivo and in vitro by tetrodotoxin and was Ca2+-dependent. The uptake of [U-14C]GABA was inhibited by tityustoxin but this action was prevented by tetrodotoxin (1 microM). Since the release of [U-14C]GABA from synaptosomes due to the tityustoxin was also prevented by tetrodotoxin under identical circumstances, it is concluded that the tityustoxin has a primary action on release of neurotransmitters rather than on uptake.     

Changes inγ-aminobutyric acid during different stages of picrotoxin-induced seizure,and the effect of pretreatment withγ-acetylenic GABA and phenobarbital

Changes in GABA content of various brain areas during different stages of picrotoxin-induced seizures and following pretreatment with the anti-convulsants phenobarbital andγ-acetylenic GABA were studied. Picrotoxin (6mg/kg) produced clonic/tonic convulsions associated with a 34% reduction in GABA content of the sensory motor cortex. A reduction of 24% was observed 1 min before the onset of seizure and the reduction in GABA content was reversible 20 min after the convulsion. No significant changes were observed in the cerebellum or spinal cord/medulla oblongata. Pretreatment with phenobarbital (100mg/kg) delayed the onset of convulsion and decreased the mortality rate without causing any change in GABA content at the pre-convulsive, convulsive or post-convulsive stages.γ-Acetylenic GABA (100mg/kg) has elevated GABA levels in different areas of the brain by 2–3-fold after 60 min treatment. This increase was reduced by 44% during the onset of picrotoxin-induced seizures. Picrotoxin convulsion can occur in the presence of normal, reduced or even elevated brain GABA content. The only consistent factor is a one-third reduction in GABA content before the onset of seizure.     

Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction

ObjectiveTo determine the effectiveness of targeted pharmacologic interventions to reverse documented pathophysiologic abnormalities in prediabetes.MethodsPatients with impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) were treated with insulin sensitizers (pioglitazone + metformin) or insulin sensitizers + exenatide on the basis of oral glucose tolerance testing-derived indices of insulin resistance and impaired b-cell function. Patients who declined pharmacologic therapy received lifestyle modification only.ResultsOne hundred five patients with IGT and/or IFG were treated with insulin sensitizers (pioglitazone + metformin) (n = 40), insulin sensitizers + exenatide (n = 47), or lifestyle modification only (n = 18). After a mean follow-up period of 8.9 months, the lifestyle modification group demonstrated no significant changes in fasting plasma glucose, plasma glucose area under the curve during oral glucose tolerance testing, insulin sensitivity, or b-cell function. In the pioglitazone + metformin group (24 hours off medication), fasting plasma glucose fell from 109 to 102 mg/dL; plasma glucose area under the curve decreased by 12.0%; insulin sensitivity and b-cell function improved by 42% and 50%, respectively (all P < .001); 14.3% converted to normal glucose tolerance; and no patient developed diabetes. In the pioglitazone + metformin + exenatide group (24 hours off medication), fasting plasma glucose fell from 109 to 98 mg/dL; plasma glucose area under the curve decreased by 21.2%; insulin sensitivity and b-cell function improved by 52% and 109%, respectively (all P < .001); 59.1% of patients with IGT reverted to normal glucose tolerance; and no patient developed diabetes.ConclusionsTargeted pathophysiologic therapy based on oral glucose tolerance test-derived measures of insulin sensitivity and b-cell function can be implemented in general internal medicine and endocrine practice and is associated with marked improvement in glucose tolerance and reversion of prediabetes to normal glucose tolerance in more than 50% of patients. (Endocr Pract. 2012;18: 342-350)     

STUDIES ON THE TRANSPORT OF GLUTAMINE IN VIVO BETWEEN THE BRAIN AND BLOOD IN THE RESTING STATE AND DURING AFFERENT ELECTRICAL STIMULATION

Abstract— In this work we have studied the effect of afferent electrical stimulation (AES) of the contralateral brachial plexus on the release of glutamine and glutamate from the cat's brain into the cerebral venous blood, at rest and during continuous infusion of L-glutamine and sucrose solutions.
(1) In the resting state, before stimulation, there was a net outflow of glutamine from the brain into the cerebral venous blood, but no release of glutamic acid. (2) AES caused release of glutamate and increased 3.5-fold the release of glutamine. The increase in release of glutamine and glutamate was found to be reversed very shortly after stimulation. (3) Steady intravenous infusion of a 0.3 M-gluta-mine solution for 10 min changed the negative arterio-venous difference in glutamine to a positive one and increased the content in brain by 15×20%. In this case AES caused a singificant drop, to zero of the glutamine arterio-venous difference. (4) At the onset of pentamethylenetetrazole (PTZ) seizures, like AES, there was a significant reduction of the level of glutamine in the cats'cerebral cortex. This reduction vanished when the animals were infused with L-glutamine solution but not with 0.3 M-sucrose solution that was used as an inert electrolyte. (5) The kinetic behaviour of the glutamine transport is compatible with a carrier-mediated process, but not with passive diffusion.     

Abstrakt interacts with and regulates the expression of sorting nexin-2

Protein sorting through vesicular compartments is highly regulated to maintain the integrity and signaling of intracellular organelles in eukaryotic cells. Sorting Nexin-2 (SNX2) is involved in protein sorting in the trans-Golgi network, endosome, and/or lysosome compartments, with loss of function leading to defect in protein sorting and stress on organelles. To investigate the function of SNX2, we have identified the DEAD-box helicase Abstrakt (Abs) as an SNX2-interacting protein. The N-terminal domain of Abs interacts with the phox homology (PX) domain of SNX2 suggesting that PX domains may also participate in protein-protein interaction. Interestingly, both proteins undergo nucleocytoplasmic shuttling, and this process is responsive to serum withdrawal for Abs. Finally, expression of Abs reduced the cellular expression of SNX2 without altering its steady state mRNA levels. This unexpected interaction provides a novel mechanism whereby expression of proteins involved in membrane trafficking could be regulated by an RNA helicase.